Us Bancorp \De\ Spring Works Therapeutics, Inc. Transaction History

Us Bancorp \De\

$77.3 Billion
Q3 2024

A detailed history of Us Bancorp \De\ transactions in Spring Works Therapeutics, Inc. stock. As of the latest transaction made, Us Bancorp \De\ holds 2,780 shares of SWTX stock, worth $98,940. This represents 0.0% of its overall portfolio holdings.

Number of Shares

2,780

Previous 2,588 7.42%

Holding current value

$98,940

Previous $97,000 8.25%

% of portfolio

0.0%

Previous 0.0%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 28, 2024	BUY	$32.04 - $42.76 $6,151 - $8,209	192 Added 7.42%	2,780 $89,000
Q2 2024 Aug 06, 2024	BUY	$36.06 - $47.62 $7,680 - $10,143	213 Added 8.97%	2,588 $97,000
Q1 2024 May 07, 2024	BUY	$36.5 - $52.5 $72,854 - $104,790	1,996 Added 526.65%	2,375 $116,000
Q4 2023 Feb 09, 2024	SELL	$18.94 - $37.24 $3,371 - $6,628	-178 Reduced 31.96%	379 $13,000
Q2 2023 Aug 09, 2023	BUY	$23.15 - $32.71 $1,759 - $2,485	76 Added 15.8%	557 $14,000
Q1 2023 May 09, 2023	BUY	$24.97 - $34.05 $7,291 - $9,942	292 Added 154.5%	481 $12,000
Q4 2022 Feb 13, 2023	SELL	$21.73 - $28.72 $62,604 - $82,742	-2,881 Reduced 93.84%	189 $4,000
Q3 2022 Oct 27, 2022	SELL	$24.1 - $39.66 $4,241 - $6,980	-176 Reduced 5.42%	3,070 $87,000
Q2 2022 Aug 01, 2022	BUY	$18.36 - $60.07 $10,208 - $33,398	556 Added 20.67%	3,246 $80,000
Q1 2022 May 11, 2022	BUY	$48.97 - $65.46 $1,420 - $1,898	29 Added 1.09%	2,690 $152,000
Q4 2021 Feb 11, 2022	BUY	$53.3 - $75.84 $65,932 - $93,814	1,237 Added 86.87%	2,661 $165,000
Q3 2021 Nov 10, 2021	BUY	$62.66 - $88.26 $75,567 - $106,441	1,206 Added 553.21%	1,424 $91,000
Q2 2021 Aug 05, 2021	BUY	$67.45 - $85.63 $12,613 - $16,012	187 Added 603.23%	218 $18,000
Q1 2021 Apr 28, 2021	BUY	$65.1 - $93.59 $2,018 - $2,901	31 New	31 $2,000

Others Institutions Holding SWTX

# of Institutions

237

Shares Held

68.9M

Call Options Held

144K

Put Options Held

257K

View Full List

About SpringWorks Therapeutics, Inc.

Ticker SWTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,401,100
Market Cap $2.22B
Description
SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also deve...

More about SWTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Us Bancorp \De\, based on Form 13F filings with the SEC.

News

Stay updated on Us Bancorp \De\ with notifications on news.

Account